BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 10964596)

  • 1. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
    Zhang Y; Dawson VL; Dawson TM
    Neurobiol Dis; 2000 Aug; 7(4):240-50. PubMed ID: 10964596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
    Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
    Sidhu A; Wersinger C; Vernier P
    FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
    Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic contributions to Parkinson's disease.
    Huang Y; Cheung L; Rowe D; Halliday G
    Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into Parkinson's disease.
    Chung KK; Dawson VL; Dawson TM
    J Neurol; 2003 Oct; 250 Suppl 3():III15-24. PubMed ID: 14579120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the role of defective genes in Parkinson's disease.
    Dawson TM
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S248-9. PubMed ID: 18267244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
    Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
    Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of JNK pathway in familial Parkinson's disease].
    Jankowski M
    Postepy Biochem; 2007; 53(3):297-303. PubMed ID: 18399358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.